# Costimulation

Source: https://onco.cc/terms/costimulation/  
OnCo record `costimulation` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Additional receptor contacts help shape a T cell's response to a recognised target.

## Summary

Costimulation supplies supporting interactions alongside antigen recognition. CD28 engagement by B7 supported proliferation and interleukin-2 responses in Linsley and colleagues' controlled experiments. CTLA-4 shares CD80/CD86 ligands with CD28 and can remove these ligands from opposing cells by trans-endocytosis, reducing available costimulation. Supporting contacts do not determine a new antigen specificity.

Compare the same recognition stimulus with and without supporting contacts, with viable-cell, stimulus and pathway controls. Measure division, cytokines and killing separately. Identical peptide-HLA displays can have different supporting contexts. CD28 dependence of PD-1 rescue was demonstrated in chronic-infection and tumour-bearing mouse systems; proliferating blood CD8 cells after treatment in lung-cancer patients were predominantly CD28-positive. This does not validate CD28 abundance as a universal treatment-selection test. Engineered supporting domains require product-specific safety and efficacy evidence.

## Fields

- Kind: Term
- Last checked: 2026-11-09
- Also known as: co-stimulation; T-cell costimulation

## Notes

- Costimulation consists of additional supporting receptor interactions alongside antigen recognition, affecting activation, survival, division or differentiation. CD28 is one example, not the whole category or a universal threshold. The same peptide-HLA stimulus can receive different support without changing antigen specificity. Blocking inhibition and adding support are distinct interventions.
- Compare the same recognition stimulus with and without a specified supporting interaction, using recognition-only, viable-cell and inhibitory-context controls. Measure division, cytokines and killing separately; marker abundance does not establish causal signalling. Engineered intracellular supporting domains change receptor architecture but require product-specific persistence, safety and efficacy tests.
- Source scope: teaching synthesis checked against the cited abstracts and specified accessible primary text on 9 November 2026; fictional examples are not clinical observations or treatment-selection rules.
- A schematic comparison can keep peptide-HLA recognition the same while adding support through CD28 in one condition. Showing no supporting contact in the other condition does not establish that its T cells lack CD28. Signal strength, duration, cell state, location and inhibitory context also shape the response. CTLA-4 can transfer CD80/CD86 from an opposing cell into the cell that carries CTLA-4 by trans-endocytosis, reducing the ligands available for CD28. Measure division, cytokines and killing under matched conditions. Neither this contact comparison nor ligand removal justifies eliminating every inhibitory input or establishes a universal response threshold.

## Sources

- Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation.: https://pubmed.ncbi.nlm.nih.gov/1847722/
- Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4.: https://pubmed.ncbi.nlm.nih.gov/21474713/
- Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.: https://pubmed.ncbi.nlm.nih.gov/28280249/

## Connected records

- terms: [T cell](https://onco.cc/terms/t-cell/)

---
JSON: https://onco.cc/api/v1/entities/costimulation.json